ChemoMetec ASOCSE:CHEMM +0.38%99 ROA % is 23.33% as of Dec. 2025, which is 1% below its 10-year median of 23.68. GuruFocus rates OCSE:CHEMM with a GF Score™ of 99/100 and a GF Value™ of kr523.33 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 857 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 97.78% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ChemoMetec AS's annualizedNet Income for the quarter that ended in Dec. 2025 was kr188.0 Mil.
ChemoMetec AS's average Total Assets over the quarter that ended in Dec. 2025 was kr805.7 Mil. Therefore, ChemoMetec AS's annualized ROA % for the quarter that ended in Dec. 2025 was 23.33%.
The historical rank and industry rank for ChemoMetec AS's ROA % or its related term are showing as below:
OCSE:CHEMM'
s ROA % Range Over the Past 10 Years
Min: 7.96 Med: 23.68 Max: 37.69
Current: 22.68
During the past 13 years, ChemoMetec AS's highest ROA % was 37.69%. The lowest was 7.96%. And the median was 23.68%.
OCSE:CHEMM's ROA % is ranked better than 97.78% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.56
vs OCSE:CHEMM: 22.68
ChemoMetec AS (OCSE:CHEMM) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
ChemoMetec AS ROA % Related Terms
ChemoMetec AS ROA % Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, ChemoMetec AS's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's ROA % distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
ChemoMetec AS (OCSE:CHEMM) has a ROA % of 23.33% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on ChemoMetec AS and its competitors. This is near median its historical median of 23.68. Over the past decade, ChemoMetec AS's ROA % has ranged from 7.96 to 37.69. According to the industry distribution chart, ChemoMetec AS ranks #19 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 2.2%.
Is ChemoMetec AS's ROA % too high?
ChemoMetec AS's current ROA % of 23.33% is near median its 10-year median of 23.68. Over the past 10 years, this metric has ranged from a low of 7.96 to a high of 37.69. The Medical Devices & Instruments industry median ROA % is 0.56. ChemoMetec AS's value of 23.33% is 4066.1% above this industry median. Based on the distribution chart, ChemoMetec AS ranks #19 out of 857 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ChemoMetec AS has a GF Score™ of 99/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's ROA % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #19 out of 857 companies for ROA %. This places ChemoMetec AS in the top 2% of its industry — outperforming the majority of peers. The industry median ROA % is 0.56. ChemoMetec AS's value of 23.33% is 4066.1% above this benchmark. Historically, ChemoMetec AS's own ROA % has ranged from 7.96 to 37.69 over the past decade. While the company's 10-year median is 23.68 vs. the industry median of 0.56, ChemoMetec AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.56, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current ROA % of 23.33% is 4066.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on ChemoMetec AS and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current ROA % is 23.33%, which is near median its own 10-year median of 23.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr523.33, compared to a current price of kr370.60 — trading 29.2% below its estimated fair value. The current ROA % is 23.33%, which is near median its 10-year median of 23.68 and 4066.1% above the Medical Devices & Instruments industry median of 0.56. ChemoMetec AS's overall GF Score™ is 99/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current ROA % is 23.33% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr370.60 is trading 29.2% below its estimated GF Value™ of kr523.33.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
ROA %: 23.33% (near median its 10-year median of 23.68)
GF Value™: kr523.33 vs. price of kr370.60 (29.2% below fair value)
Industry Position: 4066.1% above the Medical Devices & Instruments median (#19 of 857)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
99GF Score
Get the complete analysis for OCSE:CHEMM
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
